Loading…
Loading…
ENZC does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ENZC and 80,000+ other tickers.
See exactly how ENZC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ENZC and 80,000+ other tickers.
Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary…
FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, has issued its first report under the recently announced collaborative agreement executed on September 9, 2024. The purpose of the study, which was sponsored by Rosetta, LLC, was to ascertain any pathological deviations as a result of the use of ENZC's exclusively licensed experimental cancer lyophilized pepsin treatment's key active ingredient, Irreversible Pepsin Fraction ("IPF"), on the Kidney, Liver, Lymph Nodes and Spleen, measure the increased activation of the immune system, determine any side effects from the use of the compound and establish survivability of the animals (mouse model on Balb/c inbred mouse line under specific pathogen free sterile conditions) used in the study.
ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology, Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, entered into a three year agreement to combine their efforts to accelerate discovery of combined applications and commercialization of their individual entity technologies. The initial focus will be combining Monoclonal Antibodies and Immune Therapeutic Proteins ("ITP") for the development of treatments of malignant antigens.
ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria concluded that inventor Harry Zhabilov's patented experimental cancer lyophilized pepsin treatment, exclusively licensed to Enzolytics, is effective in decreasing the growth and spread of cancer cells in breast cancer, colon cancer, prostate cancer, cancer of the larynx, as well as small cell lung cancer. The Conclusion of the report by Associate Professor Petya Genova-Kalu and Professor Dr. Iva Hristova, in its entirety reads as follows: "A polypeptide complex of lyophilized pepsin, causes cytopathological changes and significantly reduces the survival and/or proliferative activity of the cell cultures used as experimental models.
As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Department of Immunology, Bulgarian Academy of Science The Stephan Angeloff Institute of Microbiology have initiated a cooperative effort to expand the use of each other's technology. The main area of research by the Department of Immunology, through its seven state of the art laboratory facilities, is concentrated on: autoimmunity and autoimmune diseases, allergy, vaccines, cancer and immunomodulators.
Updates on Results of Litigation ALLEN, TX / ACCESSWIRE / July 29, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration Agreement with Elimus, Ltd ("Elimus"), a Bulgarian company located in Sofia, for the manufacturing, development and marketing of new and existing nutraceutical products of the two entities. The product license will be for the territory of North America (the United States, Canada and Mexico).